Testicular yolk sac carcinoma in infants: natural history in 56 consecutive patients
Related Experiment Videos
Insights
Yolk sac tumors in young patients show varying survival rates based on age and tumor size. Early detection and treatment are crucial for better outcomes in pediatric yolk sac tumor patients.
Area of Science:
- Pediatric Oncology
- Tumor Biology
- Clinical Epidemiology
Background:
- Yolk sac tumors (YST) are rare germ cell tumors predominantly affecting children.
- Understanding prognostic factors in YST is critical for effective treatment strategies.
Purpose of the Study:
- To analyze survival rates and prognostic factors for yolk sac tumors in a pediatric cohort.
- To identify key clinical and pathological features associated with patient outcomes.
Main Methods:
- Retrospective analysis of 56 patients diagnosed with yolk sac tumors between 1952 and 1980.
- Evaluation of patient age, tumor size, presence of metastases, and clinical stage at diagnosis.
- Assessment of 3-year survival rates post-diagnosis and treatment.
Main Results:
- Overall, 30.3% of patients survived 3 years post-diagnosis.
- Younger patients (<2 years) had higher survival rates (44%) compared to older patients (17.2%).
- Tumor size (≥6 cm) and presence of metastases at diagnosis significantly correlated with poorer survival.
Conclusions:
- Age at diagnosis, tumor size, and metastatic status are significant prognostic indicators for pediatric yolk sac tumors.
- Early-stage disease and smaller tumor size are associated with improved survival.
- Long-term survival suggests a low risk of recurrence in successfully treated young patients.
Abstract:
Fifty six patients with yolk sac tumor are registered in the "Instituto Nacional de Enfermedades Neoplásicas" (Lima-Peru), from 1952-1980: 48.22% were less than 2 years of age; 51.78% were beyond that age.- Seventeen patients survived 3 years post diagnosis: 44% when patients less than 2 years of age and 17.2% when over two years of age. 25.9% of the patients less than 2 years of age were found to have metastases whereas 48.5% when over 2 years of age. 21/56 already had metastases when first seen. All tumors were greater than or equal to 3 cm. in diameter when first seen. Metastases were found in 38% of cases when tumors were less than or equal to 6 cm., compared to 61.9% of cases in which tumors exceeded 6 cm. 51.8% of clinical stage I survived 3 years without evidence of disease; 14.3% when stage II while none survived at clinical stage IV. It is to be expected that young patients who survive 3 years after diagnosis and treatment will not suffer a recurrence of the disease.